Individual dose of tofacitinib based on pharmacokinetic and pharmacogenomic analysis
Project/Area Number |
26860100
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Shiga University of Medical Science |
Principal Investigator |
Hira Daiki 滋賀医科大学, 医学部, 特任助教 (50636959)
|
Research Collaborator |
TERADA TOMOHIRO 滋賀医科大学, 医学部, 教授 (10324641)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 個別医療 / トファシチニブ / 薬物動態 / 関節リウマチ |
Outline of Final Research Achievements |
The aim of the present study is to develop the individual dose of tofacitinib, which is a novel synthetic disease modifying anti-rheumatic drug (DMARD) that selectively inhibits Janus kinase (JAKs), particularly JAK1 and JAK3. In the present study, a novel and simple HPLC-UV assay method for the estimation of tofacinib concentration has been developed and validated. Transport characteristics of ABCB1 (P-glycoprotein, P-gp) and ABCG2 (breast cancer resistance protein, BCRP) were assessed by HEK293 cells stably expressing ABCB1 and ABCG2. The cellular accumulation of tofacitinib in HEK293-ABCB1 and HEK293-ABCG2 were markedly decreased than that in HEK293 cell as a control. These findings suggest that pharmacogenomic analysis help to optimize the individual dose of tofacitinib.
|
Report
(4 results)
Research Products
(11 results)
-
[Journal Article] Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy2017
Author(s)
Koide H, Hira D, Tsujimoto M, Katsube Y, Minegaki T, Uzu T, Ikeda Y, Morita SY, Nishiguchi K, Terada T.
-
Journal Title
Biological and Pharmaceutical Bulletin
Volume: 40
Issue: 5
Pages: 681-686
DOI
NAID
ISSN
0918-6158, 1347-5215
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
[Journal Article] Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer.2015
Author(s)
Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T
-
Journal Title
Clinical Genitourinary Cancer
Volume: in press
Issue: 4
Pages: 350-358
DOI
Related Report
Peer Reviewed
-
-
-
-
-